Omda AS (OSL:OMDA)
Norway · Delayed Price · Currency is NOK 50.00
-0.80 (-1.57%)
At close: Aug 4, 2025
Blueprint Medicines Revenue
Omda AS had revenue of 121.44M NOK in the quarter ending March 31, 2025, with 15.04% growth. This brings the company's revenue in the last twelve months to 442.14M, up 6.39% year-over-year. In the year 2024, Omda AS had annual revenue of 426.27M with 3.44% growth.
Revenue (ttm)
442.14M
Revenue Growth
+6.39%
P/S Ratio
2.32
Revenue / Employee
1.53M
Employees
268
Market Cap
1.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 426.27M | 14.16M | 3.44% |
| Dec 31, 2023 | 412.10M | 43.94M | 11.93% |
| Dec 31, 2022 | 368.17M | 37.65M | 11.39% |
| Dec 31, 2021 | 330.52M | 101.24M | 44.16% |
| Dec 31, 2020 | 229.28M | 22.05M | 10.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 603.92M |
| Nordhealth AS | 545.88M |
| Photocure ASA | 522.89M |
| Vistin Pharma ASA | 440.66M |
| ArcticZymes Technologies ASA | 102.97M |
| Gentian Diagnostics ASA | 163.38M |
| Lytix Biopharma AS | 608.00K |
| Nykode Therapeutics AS | 87.09M |